Between ages 2 and 21 and have High Grade Glioma (HGG) research hub

An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies

This study is looking at a medicine called lenvatinib for children and young people (aged 2-21) with certain types of cancer that haven't responded to other treatments. It wants to see if the medicine can shrink tumours and if it's safe to use.